Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study-Reference-Cited by-同舟云学术

Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study

Published:2015-05-28 Issue:4 Volume:80 Page:716-726
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Zeitoun Jean-David¹²³,Lefèvre Jérémie H.⁴⁵,Downing Nicholas S.⁶,Bergeron Henri¹⁷,Ross Joseph S.⁶⁸⁹

Affiliation:

1. Sciences Po; Paris France

2. Department of Gastroenterology and Nutrition; Saint-Antoine Hospital, APHP; Paris

3. Department of Proctology; Croix Saint-Simon Hospital; Paris France

4. Department of General and Digestive Surgery; Saint-Antoine Hospital, APHP; Paris France

5. University Paris VI; Paris France

6. Center for Outcomes Research and Evaluation; Yale-New Haven Hospital; New Haven Connecticut USA

7. Senior Research Fellow at the National Centre for Scientific Research (CNRS); France

8. Section of General Internal Medicine and the Robert Wood Johnson Clinical Scholars Program, Department of Internal Medicine; Yale University School of Medicine

9. Department of Health Policy and Management; Yale University School of Public Health; New Haven Connecticut USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12643/fullpdf

Reference17 articles.

1. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma;Eichler;Nat Rev Drug Discov,2008

2. Adaptive licensing: taking the next step in the evolution of drug approval;Eichler;Clin Pharmacol Ther,2012

3. Expediting drug development - the FDA's new “breakthrough therapy” designation;Sherman;N Engl J Med,2013

4. http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000109.jsp&mid=WC0b01ac0580028a47

5. http://ec.europa.eu/health/documents/eudralex/index_en.htm

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure;Scientific Reports;2024-04-20

2. Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018;Orphanet Journal of Rare Diseases;2022-01-04

3. Signals from the Dutch national spontaneous reporting system: Characteristics and regulatory actions;Pharmacoepidemiology and Drug Safety;2021-04-21

4. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States;The Milbank Quarterly;2020-10-06

5. International and temporal comparative analysis of UK and US drug safety regulation in changing political contexts;Social Science & Medicine;2020-06